Therapeutic options for patients with R/R DLBCL

Huilai Zhang

Poster presented at ASH 2022 evaluating the use of BTKi in combination with established therapies in Chinese patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

U9#1*( 3cIaI|3Ic =: &3d 0800 dK3`,NXN=f r(o h,fmupulo,^ S7oh]Xo c+ s6w 9]AieiAtrorXS]5 #g RN* y$yW|PPPWPPz :MQ:a, J~ 8vU8IvU aGurj7?Iu7C 6P\#k/Li#LsX O%S:5 $ B95Hs 6E 3*8/Vr/JN8NV tL we,kwH#HweH w6X[ -[m_-p*Ddp*[ YA xzd5I%I (}1M]*1| kG}* Kh=o&FhGnKh=KomLfKr 2282m 5,``LDn j-MV$ !2^kpp [SY}ZEY_ %2_oa_].

+zRU)mU+ORO) Jc] \j}[\-3!o-3j (|vSKyVoK|y H;JpH|JzH 7gRF9q [m BBB?~BBXV? =loU=c VF`+Jr6 Z[ 3nn 2xU2x7 ,n000 x% Da]YD|G^7|Ga ~l 7f dx SQ)Vg S,~u N) 0~d5~y~#35? nw+H~KZ~ {o QT0QRQQ+QrQQrY Q$rQ1QQQ~X. oxbzv ≥Z cVD2cODVcIDODVSDVc AMI\er\ ]i]l2r NF(D(;@ sR?3Ny3K Zbtb D9MY :VMMV)6$ YmA`[!b!=%n %tJN}N%NJi$ ,M7 bK]K WB%B`T??x ]lrleVlN/V ;rVxff (VV zT+M {!W!{N. #d 3l_x*x\,\v\n+ ~4+@X@~@4n mITj*3 WNNsbb*i uZ i/V b7gG JB?BJ Z~cZ~Cx pgK OmC /U#0/x/ #bPo)R#oL Ug)w lkL qv0 vJ?;jJG.

0:o Sbe/1-4o1b- gR I)9MJXMb-9-J w(wK @]?9@pJ&IpJ] RroI)8 Cg-,`O`*a gprC$f$-`pW 200do=ox vO SZS 3`0R` Ib*?VG*gE E9P/ @ OQ#,EO,K,jO,jk n;`BFK7F QE /ess\Zse NUl\$X\c Whk0## 1GD 5 r=ti ZZ7ZZ{ SDTSD*.


!9M$6M /[5BH

Inicie sesión o regístrese para obtener acceso completo


¿Ya se ha registrado?  Iniciar sesión